APOE and Alzheimer disease: The Generation Program, which is evaluating the efficacy of CNP520 in preclinical AD, enrolls people at risk of developing symptoms of AD based on the presence of the APOE4 allele and, in APOE4 heterozygotes, the additional presence of fibrillary Aβ.